Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | TTI-622 |
Trade Name | |
Synonyms | PF07901801|PF 07901801|PF-07901801|Maplirpacept|TTI 622|TTI622 |
Drug Descriptions |
TTI-622 is a fusion protein consisting of SIRPa fused to the human IgG4 Fc region, that binds to CD47 and blocks inhibitory signaling to macrophages, resulting in increased phagocytosis of tumor cells (Cancer Res 2018;78(13 Suppl):Abstract nr 2709). |
DrugClasses | CD47 Antibody 31 Immune Checkpoint Inhibitor 149 |
CAS Registry Number | NA |
NCIT ID | C150756 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Daratumumab + TTI-622 | Daratumumab TTI-622 | 0 | 1 |
Glofitamab-gxbm + Obinutuzumab + TTI-622 | Glofitamab-gxbm Obinutuzumab TTI-622 | 0 | 1 |
Lenalidomide + Tafasitamab-cxix + TTI-622 | Lenalidomide TTI-622 Tafasitamab-cxix | 0 | 1 |
Pegylated liposomal doxorubicin + TTI-622 | Pegylated liposomal doxorubicin TTI-622 | 0 | 1 |
Pembrolizumab + TTI-622 | Pembrolizumab TTI-622 | 0 | 1 |
TTI-622 | TTI-622 | 0 | 1 |